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Although relatively rare, inherited primitive cardiac disorders (IPCDs) in athletes have a 
deep social impact since they often present as sudden cardiac death (SCD) of young and 
otherwise healthy persons. The diagnosis of these conditions is likely underestimated 
due to the lack of shared clinical criteria and to the existence of several borderline clinical 
pictures. We will focus on the clinical and molecular diagnosis of the most common 
IPCDs, namely hypertrophic cardiomyopathies, long QT syndrome, arrhythmogenic 
right ventricular cardiomyopathy, and left ventricular non-compaction. Collectively, 
these conditions account for the majority of SCD episodes and/or cardiologic clinical 
problems in athletes. In addition to the clinical and instrumental tools for the diagnosis of 
IPCD, the viral technological advances in genetic testing have facilitated the molecular 
confirmation of these conditions. However, genetic testing presents several issues: 
the limited sensitivity (globally, around 50%), the low prognostic predictive value, the 
probability to find pathogenic variants in different genes in the same patient, and the 
risk of non-interpretable results. In this review, we will analyze the pros and cons of the 
different clinical approaches for the presymptomatic identification, the diagnosis and 
management of IPCD athletes, and we will discuss the indications to the genetic testing 
for patients and their relatives, particularly focusing on the most complex scenarios, such 
as presymptomatic tests, uncertain results, and unexpected findings.
Keywords: athletes, sudden cardiac death, genetics, medical, hypertrophic cardiomyopathy, long QT syndrome, 
arrhythmogenic right ventricular displasia, isolated non-compact myocardium
iNTRODUCTiON
Inherited primitive cardiac disorders (IPCDs) comprise a wide and heterogeneous group of condi-
tions. Two major subcategories of IPCDs are universally recognized: primitive cardiomyopathies 
and primitive electric disorders of the heart. Primitive cardiomyopathies can be defined as disorders 
characterized by morphologically and functionally abnormal myocardium, in the absence of other 
diseases that can cause the observed cardiac phenotype (1). This definition is aimed at distinguishing 
primitive cardiomyopathies from conditions in which the cardiac involvement is secondary to a 
systemic disorder. Primitive electric disorders are conditions characterized by the presence heart 
electric conduction disturbances with a morphologically normal myocardium (2). However, while 
TABLe 1 | The genes most commonly altered in cardiomyopathies.
Gene name Gene symbol Frequency (%)
Hypertrophic cardiomyopathy
Beta-myosin heavy chain MYH7 15–25
Cardiac myosin-binding protein C MYBPC3 15–25
Cardiac troponin T TNNT2 <5
Cardiac troponin I TNNI3 <5
Alpha-tropomyosin TPM1 <5
LIM-binding domain 3 LBD3 1–5
Ventricular regulatory myosin light chain MYL2 <2
Myosin light chain 3 MYL3 <1
Cardiac muscle alpha actin ACTC1 <1
Long QT syndrome
Potassium channel, voltage gated, member 1 
(Kv7.1; LQT1)
KCNQ1 40–55
Potassium channel, voltage gated, member 2 
(Kv11.1; LQT2)
KCNH2 30–45
Sodium channel, voltage gated, type V,  
α subunit (Nav1.5; LQT3)
SCN5A 5–10
Arrhythmogenic right ventricular cardiomyopathy
Plakophilin 2 PKP2 10–45
Desmoplakin DSP 10–15
Desmoglein DSG2 7–10
Desmocollin 2 DSC-2 2
Junction plakoglobin JUP <1
Genes that are rarely mutated have not been included [adapted from Bos et al. (11), 
Mizusawa et al. (12), and Iyer and Chin (13)].
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the pathophysiological mechanisms are different, the two groups 
of IPCDs encompass a continuous spectrum of diseases: rhythm 
disturbances occur in cardiomyopathies secondary to myocardial 
disarray and are the leading cause of death. Most IPCDs are 
Mendelian conditions, most commonly transmitted as autoso-
mal dominant traits with incomplete penetrance, show familial 
recurrence and have a high degree of genetic heterogeneity (many 
genes causing the same or similar phenotypes).
First level diagnostic tools are standard cardiologic investiga-
tions, such as electrocardiography (ECG) and/or echocardi-
ography (EchoCG), which can be supplemented with cardiac 
magnetic resonance and/or Holter ECG when needed (3). These 
will not be discussed in this review, since papers more focused on 
clinical aspects have been recently published (3).
The prevalence of IPCDs in general is likely underestimated, 
due to the reduced penetrance (see below), and to the existence 
of a wide gray zone between normal and definitely pathological 
instrumental findings.
In the setting of sports medicine, the identification and clinical 
management of IPCD becomes even more complex: the younger 
age of the population at risk and the presence of common features 
between IPCD and athlete heart may delay or prevent a timely 
diagnosis of these conditions; additionally, the extreme exertion 
may exacerbate underlying cardiac defects. The onset of IPCD 
symptoms in athletes is often dramatic, since these are the lead-
ing cause of sudden cardiac death (SCD). Thus, presymptomatic 
identification of affected individuals is of paramount relevance. 
Following an IPCD diagnosis, it is crucial to evaluate the eligibil-
ity for competitive or recreational sports (that implies a lesser 
cardiac impact), to establish the prognosis, to prevent the occur-
rence of fatal events, and, last but not least, to evaluate the risk for 
the athlete’s offspring and sibship.
The main relevance of genetic testing for IPCDs is in iden-
tifying at risk subjects or to solve diagnostic uncertainties. The 
most commonly altered genes involved in IPCDs are listed in 
Table 1. The introduction of next-generation sequencing (NGS) 
platforms in diagnostic laboratories and the consequential reduc-
tion of costs of molecular analysis per patient have improved the 
diagnostic yield and reduced the time interval between sampling 
and final reports. However, the data accrued have revealed the 
complexity of the genetics of IPCD (4–10). With the traditional 
Sanger sequencing diagnostic approach, single genes were 
investigated sequentially, one after another, and often testing 
was interrupted when a pathogenic or likely pathogenic variant 
was found. NGS-based approaches allow to test several genes 
simultaneously. As a consequence, the finding of individuals 
carrying ≥2 rare pathogenic or potentially pathogenic variants 
in the same or different genes has become not uncommon. At the 
same time, there has been a surge in the numbers of variants of 
uncertain significance (VUS) detected. Moreover, it has become 
clear that allelic variants in the same gene can be associated 
with different phenotypes, increasing the difficulties inherent to 
the interpretation of genetic test results. These findings suggest 
that the variable phenotypic spectrum of IPCDs cannot be only 
accounted for by classical Mendelian mechanisms, and point 
toward the involvement of an oligogenic model with strong 
environmental influences.
In this review, we will focus on the clinical and molecular 
diagnosis of the most common IPCDs in athletes, namely hyper-
trophic cardiomyopathies (HCMs), long QT syndrome (LQTS), 
arrhythmogenic right ventricular cardiomyopathy (ARVC), and 
left ventricular non-compaction (LVNC). We will also discuss 
about the TTN gene, one of the largest genes in our genome 
encoding for the giant protein Titin, which is often altered in dif-
ferent clinical conditions. We will finally discuss the prognostic 
utility of genetic testing, and the counseling approaches to IPCD 
patients and their families.
HYPeRTROPHiC CARDiOMYOPATHieS
Hypertrophic cardiomyopathies belong to the wider spectrum 
of cardiomyopathies that include also the dilative and restrictive 
phenotypes. HCM is diagnosed on the basis of left ventricular 
hypertrophy, in the absence of abnormal loading conditions. The 
estimated prevalence in the young adults is about 0.1–0.2%, which 
does not likely reflect the prevalence in the general population that 
is expected to be higher (14): available data have been obtained 
through clinical studies, and thus do not take into account the 
ascertainment biases related to later onset of symptoms and to 
the presence of borderline patients (14). According to studies 
performed in the US, HCM is the most common cause of SCD in 
young athletes (15–17); it is noteworthy that in countries where 
the preparticipation screening by ECG is mandatory by law, the 
incidence of HCM as cause of SCD among athletes is dramatically 
lower (18).
About half of HCM cases are familial with an autosomal 
dominant pattern of inheritance. More than 20 genes have been 






450–459 ms (in males) 1
B. QTcb fourth minute of recovery from exercise stress
Test ≥480 ms 1
C. Torsade de pointesc 2
D. T wave alternans 1
E. Notched T wave in 3 leads 1





B. Congenital deafness 0.5
Family history
A. Family members with definite LQTSe 1
B. Unexplained sudden cardiac death below 30 years of age 
among immediate family memberse
0.5
aIn the absence of medications or disorders known to affect these electrocardiographic 
features.
bQTc calculated by Bazett’s formula where QTc = QT/√RR.
cMutually exclusive.
dResting heart rate below the second percentile for age.
eThe same family member cannot be counted in A and B.
Score: ≤1 point: low probability of LQTS; 1.5–3 points: intermediate probability of 
LQTS; ≥3.5 points high probability.
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related to HCM: b-myosin heavy chain (MYH7) and cardiac 
myosin-binding protein C (MYBPC3) account for about 50% 
of the cases; the other genes are rarely affected, with some 
involved in a single family so far. Incomplete penetrance is 
an important issue for HCM management. Environmental 
factors (such as intense training) and/or modifier genes may 
increase the risk of clinical manifestations especially during 
exercise or sport. If this was the case, one should expect to find 
more frequently clinical/instrumental signs of HCM among 
athletes compared with the general population. However, to 
the best of our knowledge, there are no available data on the 
true prevalence of HCM among professional athletes. Since the 
main complication of this condition is sudden death, the devel-
opment of primary prevention programs aimed at identifying 
at risk subjects is very important, despite the relatively low 
frequency of HCM (16–18). There are not yet enough sensitive 
clinical markers that may help to identify HCM patients at risk 
of sudden death. The most reliable predictors are family history 
of sudden death related to HCM, syncope or presyncope events, 
ventricular tachyarrhythmia, marked hypotension during 
training, extreme left ventricle hypertrophy, and extended late 
enhancement at cardiac MRI (19–22), but their performance 
is far from satisfactory. A quantitative approach for the assess-
ment of the risk of sudden death in HCM has been reported 
by O’Mahony et al. (23), the so-called HCM risk SCD. In this 
case, the risk is estimated on the basis of data collected in a 
retrospective longitudinal study by taking into account differ-
ent variables.
Rather than for patients with clear HCM phenotypes, genetic 
testing may be useful for the proper interpretation of borderline 
patients falling in the gray zone. However, reduced penetrance, 
genetic heterogeneity, and high VUS frequency make the 
interpretation of the clinical significance of genetic variants chal-
lenging. Furthermore, a preliminary NGS-based study reported 
the occurrence of double heterozygosity in a high proportion 
of HCM patients, 2 of the 11 patients with pathogenic variants. 
These patients were reported as having a more severe phenotype 
compared with patients with a single disease causing variant (24).
With regard to practical implications for molecular diagnosis, 
according to the guidelines of the European Society of Cardiology 
(ESC), genetic testing could be offered to all patients fulfilling 
the HCM diagnostic criteria. Irrespective of the sequencing 
methodology employed, genetic analysis should include the most 
commonly implicated sarcomere protein genes (1). Following 
the identification of a definite pathogenic variant in the proband, 
genetic testing can be offered to all relatives on a voluntary basis. 
If no causative variants are found in the proband, relatives should 
be advised to undergo clinical reassessment should symptoms of 
HCM manifest.
LONG QT SYNDROMe
Long QT syndrome is defined by the finding of a prolonged QT 
interval in standard ECG recording. It is generally accepted that 
the normal duration of the QT interval is 0.37–0.44 s. Based on 
this criterion, the diagnosis of LQTS is apparently easy, but 15% 
of subjects in the general population have a QT interval >0.44 s 
(0.44–0.47 s) and 25–35% of individuals with a pathogenic vari-
ant in one of the LQTS genes has a normal QT interval (25, 26). 
This latter observation deserves some additional comments: at 
this stage, it is very difficult to establish whether the finding of 
a variant considered disease causing in asymptomatic patients 
is due to reduced penetrance or if, in the light of more recent 
concepts of molecular genetics, it is the consequence of a wrong 
interpretation, and the observed DNA change in a VUS, or even 
a rare benign, not clinically relevant, variation.
Since the diagnostic value of QT interval measurement on 
its own is not sufficient, a scoring method based on multiple 
parameters is currently used [Table 2; (27)]. LQTS belongs to the 
wider nosologic group of the channelopathies, and its cumulative 
prevalence is about 1/2,500: as in the case of HCM, this is likely 
an underestimate, due to the wide phenotypic heterogeneity. 
The majority of cases are familial (about 90%). As in the case of 
HCM, few genes account for the vast majority of cases: specifi-
cally, defects in KCNQ1, KCNH2, and SCN5A are found in about 
80% of patients. Double heterozygotes are not uncommon: two 
pathogenic or likely pathogenic variants in different genes are 
observed in about 10% of patients, and these often display more 
severe phenotypes (28).
The diagnosis of LQTS in athletes is complicated by the cor-
relation between duration of the QTc interval and exercise, and 
the extreme variation of heart rate reached by athletes. In two 
studies, the prevalence of LQT was 0.6 and 0.4% in an Italian and 
a British athlete population, respectively (29, 30), that is about 
10- to 15-fold higher than in the general population. In the British 
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study, molecular screening of KCNQ1, KCNH2, and SCN5A was 
performed in five of the seven patients with LQT, three of whom 
had a QT interval >0.50 s and additional signs reinforcing the 
suspicion of LQTS; a pathogenic variant was found only in one 
patient. However, the apparently low yield of genetic testing in 
this cohort of patients could be related to technical limitations. 
A proper diagnosis of LQTS in athletes is of particular relevance: 
besides the obvious implications for the patient and the family, 
it entails also important career implications, since it is suggested 
that it may represent a contraindication to competitive sport 




Arrhythmogenic right ventricular cardiomyopathy is a cardiac 
muscle disease characterized by life-threatening ventricular 
arrhythmias. The estimated prevalence is about 1:2,500–5,000. 
ARVC is considered one of the major causes of sudden death 
in young individuals and in athletes (18). ARVC is generally 
associated with ECG alterations, including negative T wave in 
right precordial leads, ventricular arrhythmias with a left bundle 
branch block morphology, epsilon waves, and others. However, 
some of these abnormalities are not specific and may be found in 
other pathological conditions with a different prognosis, such as 
myocarditis (34). The extensive use of ECG screening may help 
the sports physician to suspect the diagnosis, while genetic testing 
may be very useful for the differential diagnosis with more benign 
conditions.
Cardiac pathology shows dystrophy of the right ventricular 
myocardium with fibrofatty replacement. The clinical picture 
may include a subclinical asymptomatic phase; ventricular 
fibrillation, or an electrical disorder with palpitations and 
syncope, due to tachyarrhythmias of right ventricular origin, 
may be the first presentation. Most ARVC genes encode for 
proteins of mechanical cell junctions (DSC2, DSG2, DSP, PKP2, 
JUP, and DES), while others encode for structural proteins of 
the nuclear membrane (LMNA and TMEM43) or membrane 
channels (RYR2). ARVC has an autosomal dominant pattern of 
inheritance with incomplete penetrance. Pathogenic variations 
in the nine ARVC genes identified so far account for about 50% 
of cases. Double heterozygotes have been reported also in this 
condition. Clinical diagnosis may be achieved by demonstrating 
functional and structural alterations of the right ventricle, depo-
larization and repolarization abnormalities, arrhythmias with 
left bundle branch block morphology, and fibrofatty replacement 
upon endomyocardial biopsy [see Basso et al. (35) for a review]. 
Albeit rare, the diagnosis of ARVC is of crucial importance for 
athletes, due to the risk of sudden death: the condition was origi-
nally described as the most common cause of death in sports-
men. However, it is now evident that the condition has a wide 
phenotypic variability, including very mild asymptomatic cases: 
sport activity may increase the risk of ventricular arrhythmias in 
asymptomatic subjects with pathogenic variants in desmosomal 
genes (36).
LeFT veNTRiCULAR NON-COMPACTiON
Left ventricular non-compaction is due to the precocious arrest of 
myocardial compaction during the first weeks of the embryonic 
development. This causes persistence of prominent trabeculae in 
the ventricular cavity. The disease spectrum is very wide: the first 
reported cases were of patients with a marked dilation of the left 
ventricle and high risk of death (37–40), but asymptomatic and 
barely progressive segmental forms have also been reported, in 
which the lack of compaction involves only part of the left ven-
tricle. LVNC is a rare disorder with prevalence <0.1%, although 
it has been increasingly diagnosed over the last few years. Similar 
to many other rare disorders, with increasing knowledge its diag-
nosis has become more common, and among newly identified 
cases, there is an increasing proportion of asymptomatic subjects, 
including athletes, with mild phenotypic expression. Indeed, 
heart hypertrabeculation has been observed in up to 18.3% of 
athletes (41), about 8% of which fulfill the diagnostic criteria of 
LVNC. In our experience, a multiparametric evaluation, based on 
morphological and functional parameters, such as the thickness 
of the residual compact layer and the presence of major conduc-
tion defects and arrhythmias, may help to discriminate between 
true cardiomyopathies and “benign” forms of LVNC (42). In the 
latter group of patients, the risk of sudden death, heart failure, 
and life-threatening arrhythmias is likely low. In any case, close 
follow-up is still recommended.
Genetic testing is not particularly useful for the molecular 
confirmation of LVNC for at least two reasons: the detection 
rate of pathogenic variants is relatively low, about 40%, and 
the genes involved in LVNC are also responsible also for other 
cardiomyopathies, complicating the interpretation of positive test 
results (43). Based on these findings, it has been proposed that 
LVNC may be a phenotypic variant of other cardiomyopathies, 
characterized by impaired general development of the sarcomeric 
proteins: this pathogenic model is supported by the cooccurrence 
in the same family of LVNC and different cardiomyopathies. It is 
conceivable that genetic background and environmental factors 
may play a relevant role in the onset of LVNC (44).
Regarding the relationship with sport activity, the number of 
incidental diagnoses has increased over time, often in asympto-
matic athletes. Of note, hypertrabeculation of the left ventricle 
may physiologically occur in athletes, particularly in elite and 
black sportsmen. Thus, it is crucial to distinguish between the 
true cardiomyopathy and the benign segmental LVNC for the 
assessment of the risk of serious life-threatening events (45).
TiTiN: A TiTAN OR A GiANT  
wiTH CLAY FeeT?
Although if it is only one of the genes involved in cardiomyopa-
thies, the titin gene (TTN) deserves a separate discussion due to 
its peculiarities. TTN is one of the largest genes in our genome 
and encodes for the largest human protein. The titin protein has 
several functions in both cardiac and skeletal muscle. Due to 
the size, prior to the advent of NGS, the mutational analysis of 
TTN was limited to few exons. The exact number of isoforms 
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is unknown, although it has been estimated that at least 
one-third of TTN exons may give raise to alternative splicing 
events (46, 47). TTN has been associated with both dominant 
and recessive disorders and is currently considered one of the 
most commonly altered genes in human disease (48), causing 
at least 10 different conditions, involving skeletal muscle, heart, 
or both. However, accruing data on genomic variations in the 
general population have shown that rare TTN variants overall 
are common, with at least 2–3% of healthy individuals bearing 
monoallelic truncating mutations. Rare and private missense 
variants are extremely common as well (47, 49). We should 
then expect a prevalence of recessive pathogenic variants of 
at least 1/4,000–10,000, much higher than the cumulative 
prevalence of titinopathies. Thus, it seems that at least a part, if 
not the majority, of truncating TTN variants is benign and does 
not cause pathological phenotypes on their own. The lack of 
pathogenicity of TTN alleles potentially causing complete loss 
of function could be explained by alternative splicing events 
rescuing the gene function.
Based on these observations, the pathogenic role of TTN 
variants should be assessed cautiously, especially for the potential 
application to presymptomatic-predictive testing in healthy rela-
tives of patients in whom TTN alterations have been detected. It is 
likely that in the few next years, with accruing genomic data in the 
general population and the spreading of NGS platforms for the 
diagnosis of cardiomyopathies, the pathogenicity of TTN variants 
will be largely elucidated.
DiSCUSSiON
In this review, we have highlighted critical aspects associated 
with the clinical and genetic diagnosis of the IPCDs. The most 
recent findings on the variability of the human genome are 
quickly changing the approach to DNA variant interpretation. 
Indeed, a systematic assessment of variants, including those 
previously interpreted as pathogenic, is ongoing for several genes 
associated with inherited conditions. Overall, the following 
issues are associated with all types of IPCD and complicate their 
diagnosis and management: (1) wide genetic heterogeneity, (2) 
incomplete penetrance, (3) relatively high frequency of double 
heterozygotes, and (4) effect of environmental factors (largely 
unknown as well, besides sport activity). In the light of these 
characteristics, IPCDs could be considered as complex traits 
determined by the predominant effect of single gene variants, 
rather than as monogenic disorders. Considering IPCDs as 
oligogenic multifactorial disorders has three main implications: 
(1) genotype–phenotype correlations are unclear, (2) difficulty in 
establishing prognosis and risks for patients, and consequently, 
(3) genetic testing has a limited predictive power both in affected 
patients and in asymptomatic relatives at risk. Therefore, in 
our opinion, the use of the risk figures estimated according to 
Mendelian inheritance is not fully appropriate for predictive 
purposes. It could be useful to develop a risk assessment model 
similar to those applied for the familial predisposition to breast 
cancer, taking into account the presence of multiple factors (e.g., 
family history, level of exposure to physical activity, presence of 
multiple gene variants) (50). Indeed, with few exceptions (51–53), 
due to poor genotype–phenotype correlations, results of clinical 
investigations provide better prognostic information than those 
of genetic testing.
These problems become even more complicated in athletes, 
who can display some features resembling those of IPCD as a 
consequence of physiological rearrangements of the myocardium 
with training. These subjects, who are mostly young, present some 
additional issues: the ascertainment of a variant known to be the 
cause of an IPCD phenotype may have strong implications for the 
prosecution of their sport career, for reproductive choices, and 
for their families. The offer of a predictive test for relatives should 
be considered with caution, and only when the pathogenicity of 
the variant detected in the proband has been clearly established 
according to consensus criteria (54). The opportunity of testing 
underage relatives of athletes should also be carefully scrutinized, 
especially when presymptomatic diagnosis may be beneficial, 
such as in the case of LQTS, which can manifest as infant sudden 
death.
Variant interpretation is the main issue in molecular diag-
nosis of IPCDs, and it is further exacerbated by the small size 
of many pedigrees. This hampers analysis of variant segregation 
with respect to the phenotype, one of the most useful points of 
evidence for clinical interpretation of genetic variants, as well the 
estimation of penetrance values. Ideally, novel or unclassified 
variants should be validated by functional studies; however, with 
few exceptions, these are not performed in clinical diagnostic 
laboratories and are associated with several issues, such as the 
choice of the cellular model and feasibility, since most sarcomeric 
mRNAs are quite large and not easily manageable. In conclusion, 
unless validated functional tests have been performed, the main 
hints suggesting pathogenicity of a variant are its identification in 
different patients or de novo occurrence.
Another open issue is the significance of double heterozy-
gosity and related counseling. So far, it is common opinion that 
these subjects may in general display a more severe phenotype 
but the cohorts published so far are too small to draw definite 
conclusions.
TTN deserves separate considerations. In particular, given 
the difficulties inherent with TTN molecular testing and 
interpretation, one might wonder whether it is appropriate to 
include this gene in diagnostic panels and in genetic reports 
for patients, or rather, whether it should still be investigated 
in research settings for epidemiological purposes. These might 
shed light on the pathogenicity of TTN truncating and missense 
variants, as well as and on their clinical relevance; indeed, it 
remains to be established if TTN variants act as main pheno-
typic drivers and/or as a risk factor for the appearance of the 
clinical manifestation of some IPCDs, insufficient alone to 
determine a phenotype.
Similar to TTN, also in HCM the large amount of whole 
exome data that are accumulating in the different databases is 
disclosing that presumptive pathogenic variants can be found in 
“controls” at a higher rate than expected for the prevalence of the 
condition (55–57). On the one hand, this excess of pathogenic 
variants could be accounted for by reduced penetrance: carriers 
identified in the general population may or may not develop signs 
of HCM over time, but should be considered as asymptomatic 
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subjects. On the other hand, these findings may indicate that the 
effects of these gene variants are too weak to cause appearance 
of the phenotype on their own. In conclusion, the refinement of 
clinical diagnosis of IPCD, coupled with the new technological 
tools available in molecular genetics, has opened the Pandora box 
of cardiac primitive defects. Now, the pieces of this puzzle need 
to be reconstructed in order to provide patients and athletes with 
more accurate information and best care. But, there is still a long 
way to go.
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